The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
OBJECTIVE
To establish the clinical utility of serum soluble IL-2 receptor (sIL-2R alpha), lactate dehydrogenase (LDH) [corrected] and B2-microglobulin [corrected] (B2-M) as markers for diagnosis, prognosis and treatment monitoring in childhood soft tissue sarcomas (STS).


METHODS
The markers[corrected] were measured prospectively before treatment, in complete remission (CR) during and after therapy and at relapse [corrected] in 35 children with STS and in 50 healthy children [corrected] (once).


RESULTS
Serum sIL-2R alpha and LDH [corrected] correlated with age thus they were [corrected] presented as multiplications [corrected] of the upper normal ranges [corrected] for age. Pre-treatment levels [corrected] of sIL-2R alpha and LDH [corrected] but not of B2-M exceeded significantly those of controls. [corrected] Elevated [corrected] sIL-2R alpha levels correlated with more [corrected] advanced stages, poor-risk histology and poor response to chemotherapy, higher LDH with incomplete primary tumour [corrected] resection and increased B2-M with poor-risk histology. [corrected] Patients' age >10 years, male gender and unfavourable tumour localisation were not accompanied by the markers' elevation. [corrected] None of the markers predicted EFS and OS. [corrected] Good response to chemotherapy was paralleled by significant decline of sIL-2R alpha and LDH pre-treatment levels while relapse--by sIL-2R alpha and LDH increase to values similar to those at diagnosis. [corrected] Monitoring of B2-M did not reflect the disease course. [corrected]


CONCLUSIONS
sIL-2R alpha and LDH were [corrected] proven to be promising markers [corrected] for diagnosis and treatment monitoring in children with STS. The markers [corrected] correlated also with some [corrected] important prognostic clinico-pathological factors for childhood [corrected] STS; however, they [corrected] failed to predict EFS and OS. Measurements of serum [corrected] B2-M were shown [corrected] to have no clinical value in the diagnostics, prognostics and treatment monitoring in paediatric STS.
Bien
Ewa
E
Department of Paediatrics, Haematology, Oncology and Endocrinology, Medical University of Gdansk, 7 Debinki Street, 80-211, Gdansk, Poland. ewabien1@wp.pl
Rapala
Malgorzata
M
Krawczyk
Malgorzata
M
Balcerska
Anna
A
D000293:Adolescent; D000367:Age Factors; D014408:Biomarkers, Tumor / Q000097:blood*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood*; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012074:Remission Induction; D018570:Risk Assessment; D012307:Risk Factors; D012509:Sarcoma / Q000097:blood / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000097:blood*
D014408:Biomarkers, Tumor; D053645:Interleukin-2 Receptor alpha Subunit; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase
J Pathol. 2009 Jun;218(2):222-31
19274709
Nat Rev Cancer. 2004 Nov;4(11):891-9
15516961
Int J Biol Markers. 1995 Apr-Jun;10(2):75-80
7561242
Acta Oncol. 1996;35(4):479-82
8695165
Tumori. 1999 Mar-Apr;85(2):101-7
10363075
Mediators Inflamm. 2005 Aug 14;2005(3):171-4
16106104
Pediatr Hematol Oncol. 2007 Sep;24(6):417-30
17710659
Ann Oncol. 2001 Oct;12(10):1423-32
11762815
Int J Cancer. 2007 Jul 15;121(2):454-8
17373663
Immunol Rev. 1999 Dec;172:11-9
10631933
Cancer. 2002 Dec 15;95(12):2534-8
12467067
Curr Opin Hematol. 2006 Jul;13(4):266-72
16755224
Br J Cancer. 2000 Oct;83(7):847-52
10970683
Breast Cancer Res Treat. 2000 Feb;59(3):279-87
10832598
Int J Pancreatol. 1995 Apr;17(2):161-6
7622938
Med Pediatr Oncol. 2003 Mar;40(3):187-8
12518348
Pediatr Blood Cancer. 2008 Nov;51(5):589-92
18649370
Blood. 1989 Jun;73(8):2128-32
2786434
Eur J Intern Med. 2007 May;18(3):175-84
17449388
Cancer. 1991 May 1;67(9):2295-9
2013037
J Pediatr Surg. 2006 Jan;41(1):245-51
16410142
Paediatr Drugs. 2002;4(1):21-8
11817983
Clin Cancer Res. 2001 Nov;7(11):3504-9
11705869
Eur J Haematol. 1999 Feb;62(2):117-22
10052715
Oncologist. 2008 Jun;13(6):668-78
18586922
Wiad Lek. 2006;59(1-2):10-5
16646285
Int J Cancer. 2009 Jan 15;124(2):367-75
19003959
Blood. 1988 Apr;71(4):1172-4
3128349
J Interferon Cytokine Res. 2001 Oct;21(10):793-6
11710990
Ann Oncol. 2003 Apr;14(4):656
12649118
Anticancer Res. 1996 Jan-Feb;16(1):219-24
8615612
Int J Clin Oncol. 2002 Oct;7(5):312-7
12402066
Br J Haematol. 2005 Sep;130(5):709-15
16115126
Cancer Detect Prev. 2005;29(3):256-9
15899555
Oncology. 1988;45(3):162-5
3285279
J Clin Immunol. 2007 Jan;27(1):1-18
17216565
Int J Hematol. 2000 Aug;72(2):194-9
11039668
Cancer Immunol Immunother. 2002 Mar;51(1):53-7
11845260
Oncol Rep. 1999 Jul-Aug;6(4):807-11
10373661
World J Urol. 1999 Oct;17(5):319-23
10552152
Cytokine. 2006 Feb 7;33(3):150-5
16517174
Acta Otolaryngol. 2009 Dec;129(12):1519-23
19922107
Clin J Am Soc Nephrol. 2006 Nov;1(6):1322-30
17699365
BioDrugs. 2005;19(6):347-54
16392887
Eur J Gastroenterol Hepatol. 2000 Aug;12(8):937-9
10958222
Biomarkers. 2007 Mar-Apr;12(2):203-13
17536769
Urol Oncol. 2000 Jul 1;5(4):168-172
10869961
Int J Cancer. 2002 Aug 1;100(4):463-71
12115531
Ann Surg Oncol. 2000 Apr;7(3):239-45
10791856
Tumori. 2004 Sep-Oct;90(5):478-84
15656333
Leukemia. 1993 Aug;7(8):1242-4
8394483
Biomarkers. 2008 Feb;13(1):1-26
17906988
Pediatr Blood Cancer. 2008 Apr;50(4):739-45
18286501
Jpn J Clin Oncol. 1998 Dec;28(12):729-32
9879289
Blood. 2006 Aug 1;108(3):1007-12
16569769
J Clin Immunol. 2002 Mar;22(2):51-6
11998892
J Exp Clin Cancer Res. 2001 Dec;20(4):523-8
11876546
Wiad Lek. 2004;57(1-2):8-11
15181741
Eur J Haematol. 1999 Jul;63(1):19-25
10414450
Arch Immunol Ther Exp (Warsz). 1996;44(2-3):123-6
8915516
Clin Cancer Res. 2007 Jun 15;13(12):3591-6
17575223
Eur J Clin Invest. 1980 Aug;10(4):293-300
6159213
Haematologica. 2007 Aug;92(8):1067-74
17640855
Ann Oncol. 2008 May;19(5):970-6
18272915
Med Wieku Rozwoj. 2004 Oct-Dec;8(4 Pt 2):1081-9
15951603
Med Sci Monit. 2000 Jul-Aug;6(4):661-7
11208388
Leuk Lymphoma. 2006 Apr;47(4):603-11
16690518
Scand J Immunol. 1977;6(4):255-63
67632
J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9
18592269
Bone Marrow Transplant. 2006 Apr;37(8):731-7
16501593
Mymensingh Med J. 2008 Jul;17(2):169-73
18626453
Scand J Immunol. 1994 Jan;39(1):64-72
8290894
Lung Cancer. 1999 Jan;23(1):1-9
10100141
Bone Marrow Transplant. 2007 Oct;40(7):651-8
17660837
Lancet. 2001 Apr 21;357(9264):1263-4
11418153
Eur J Cancer. 1990 Jan;26(1):33-6
2138475